
Overview
This ambitious project seeks to characterize the genetic and epigenetic regulation of multiple facets of transcription in distinct brain regions across the human lifespan in samples of major neuropsychiatric disorders and controls. Initially focused on schizophrenia and mood disorders, the goal of this consortium is to elucidate the underlying molecular mechanisms of genetic associations with the goal of identifying novel therapeutic targets. The consortium currently consists of seven pharmaceutical companies and a not-for-profit medical research institution working as a precompetitive team to generate and analyze publicly available archival brain genomic data related to neuropsychiatric illness.
Features and programs
Open Data Sponsorship Program
Pricing
This is a publicly available data set. No subscription is required.
How can we make this page better?
Legal
Content disclaimer
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Open data resources
Available with or without an AWS account.
- How to use
- To access these resources, reference the Amazon Resource Name (ARN) using the AWS Command Line Interface (CLI). Learn more
- Description
- Phase 1: DLPFC polyA+ RNA-seq on 738 subjects spanning the lifespan and three main psychiatric diagnostic groups (Schizophrenia, Major Depression Disorder, and Bipolar Disorder).
- Resource type
- S3 bucket
- Amazon Resource Name (ARN)
- arn:aws:s3:::brainseq.opendata.sagebase.org
- AWS region
- us-east-1
- AWS CLI access (No AWS account required)
- aws s3 ls --no-sign-request s3://brainseq.opendata.sagebase.org/
Resources
Vendor resources
Support
Contact
Managed By
Sage Bionetworks
How to cite
BrainSeq - Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders was accessed on DATE from https://registry.opendata.aws/brainseq .
License
CC BY
Similar products

